FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004456466> ?p ?o ?g. }

• W2004456466 endingPage "22013" @default.
• W2004456466 startingPage "22006" @default.
• W2004456466 abstract "Vascular endothelial growth factor (VEGF) and its receptors play an essential role in the formation and maintenance of the hematopoietic and vascular compartments. The VEGF receptor-2 (VEGFR-2) is expressed on a population of hematopoietic cells, although its role in hematopoiesis is still unclear. In this report, we have utilized a strategy to selectively activate VEGFR-2 and study its effects in primary bone marrow cells. We found that VEGFR-2 can maintain the hematopoietic progenitor population in mouse bone marrow cultured in the absence of exogenous cytokines. Maintenance of the hematopoietic progenitor population is due to increased cell survival with minimal effect on proliferation. Progenitor survival is mainly mediated by activation of the phosphatidylinositol 3′-kinase/Akt pathway. Although VEGFR-2 also activated Erk1/2 mitogen-activated protein kinase, it did not induce cell proliferation, and blockade of this pathway only partially decreased VEGFR-2-mediated survival of hematopoietic progenitors. Thus, the role of VEGFR-2 in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways. Vascular endothelial growth factor (VEGF) and its receptors play an essential role in the formation and maintenance of the hematopoietic and vascular compartments. The VEGF receptor-2 (VEGFR-2) is expressed on a population of hematopoietic cells, although its role in hematopoiesis is still unclear. In this report, we have utilized a strategy to selectively activate VEGFR-2 and study its effects in primary bone marrow cells. We found that VEGFR-2 can maintain the hematopoietic progenitor population in mouse bone marrow cultured in the absence of exogenous cytokines. Maintenance of the hematopoietic progenitor population is due to increased cell survival with minimal effect on proliferation. Progenitor survival is mainly mediated by activation of the phosphatidylinositol 3′-kinase/Akt pathway. Although VEGFR-2 also activated Erk1/2 mitogen-activated protein kinase, it did not induce cell proliferation, and blockade of this pathway only partially decreased VEGFR-2-mediated survival of hematopoietic progenitors. Thus, the role of VEGFR-2 in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways. Vascular endothelial growth factor (VEGF) 1The abbreviations used are: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; PI 3-kinase, phosphatidylinositol 3′-kinase; MAP, mitogen-activated protein kinase; Erk, extracellular-regulated kinase; Flt, Fms-like tyrosine kinase; FKBP, FK506-binding protein; FBS, fetal bovine serum; EGF, epidermal growth factor; GFP, green fluorescent protein; SCF, stem cell factor; IL, interleukin; IMDM, Iscove's modified Eagle's medium; CFC, colony-forming cell; CFU-S12, colony-forming unit-spleen; BrdUrd, bromodeoxyuridine; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; HA, hemagglutinin; MIG, murine stem cell virus-internal ribosome entry site-enhanced green fluorescent protein.1The abbreviations used are: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; PI 3-kinase, phosphatidylinositol 3′-kinase; MAP, mitogen-activated protein kinase; Erk, extracellular-regulated kinase; Flt, Fms-like tyrosine kinase; FKBP, FK506-binding protein; FBS, fetal bovine serum; EGF, epidermal growth factor; GFP, green fluorescent protein; SCF, stem cell factor; IL, interleukin; IMDM, Iscove's modified Eagle's medium; CFC, colony-forming cell; CFU-S12, colony-forming unit-spleen; BrdUrd, bromodeoxyuridine; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; HA, hemagglutinin; MIG, murine stem cell virus-internal ribosome entry site-enhanced green fluorescent protein. and its two receptors, VEGFR-1 (Flt-1) and VEGFR-2 (kinase domain region/fetal liver kinase) are key regulators of vascular and hematopoietic development (1Risau W. Flamme I. Annu. Rev. Cell Dev. Biol. 1995; 11: 73-91Crossref PubMed Scopus (1320) Google Scholar, 2Carmeliet P. Collen D. Curr. Top. Microbiol. Immunol. 1999; 237: 133-158PubMed Google Scholar, 3Carmeliet P. Ferreira V. Breier G. Pollefeyt S. Kieckens L. Gertsenstein M. Fahrig M. Vandenhoeck A. Harpal K. Eberhardt C. Declercq C. Pawling J. Moons L. Collen D. Risau W. Nagy A. Nature. 1996; 380: 435-439Crossref PubMed Scopus (3403) Google Scholar). Deletion of a single VEGF allele results in abnormal blood vessel development and embryonic lethality, indicating a critical dose-dependent embryonic requirement for VEGF (3Carmeliet P. Ferreira V. Breier G. Pollefeyt S. Kieckens L. Gertsenstein M. Fahrig M. Vandenhoeck A. Harpal K. Eberhardt C. Declercq C. Pawling J. Moons L. Collen D. Risau W. Nagy A. Nature. 1996; 380: 435-439Crossref PubMed Scopus (3403) Google Scholar, 4Ferrara N. Carver-Moore K. Chen H. Dowd M. Lu L. KS O.S. Powell-Braxton L. Hillan K.J. Moore M.W. Nature. 1996; 380: 439-442Crossref PubMed Scopus (3003) Google Scholar). In VEGFR-2 knockout embryos, there are critical defects in both hematopoiesis and vasculogenesis that mirror those found in VEGF-deficient embryos (5Shalaby F. Rossant J. Yamaguchi T.P. Gertsenstein M. Wu X.F. Breitman M.L. Schuh A.C. Nature. 1995; 376: 62-66Crossref PubMed Scopus (3308) Google Scholar, 6Shalaby F. Ho J. Stanford W.L. Fischer K.D. Schuh A.C. Schwartz L. Bernstein A. Rossant J. Cell. 1997; 89: 981-990Abstract Full Text Full Text PDF PubMed Scopus (736) Google Scholar). However, the mechanisms by which VEGFR-2 affects hematopoiesis and vasculogenesis remain unclear. Although VEGFR-2 is essential for the generation of endothelial and hematopoietic cells in vivo (6Shalaby F. Ho J. Stanford W.L. Fischer K.D. Schuh A.C. Schwartz L. Bernstein A. Rossant J. Cell. 1997; 89: 981-990Abstract Full Text Full Text PDF PubMed Scopus (736) Google Scholar), these cell populations can arise in vitro in embryonic stem cells that are deficient for VEGFR-2 (7Hidaka M. Stanford W.L. Bernstein A. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 7370-7375Crossref PubMed Scopus (98) Google Scholar, 8Schuh A.C. Faloon P. Hu Q.L. Bhimani M. Choi K. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 2159-2164Crossref PubMed Scopus (187) Google Scholar), indicating that this receptor might play a conditional role in the generation of cells of the hematopoietic and endothelial lineage. This has led to the hypothesis that VEGFR-2 might exert its effects by promoting the survival, proliferation, and migration of the hemangioblast, precursor of both the hematopoietic and endothelial lineages, rather than acting as a switch that activates differentiation of the hemangioblast (8Schuh A.C. Faloon P. Hu Q.L. Bhimani M. Choi K. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 2159-2164Crossref PubMed Scopus (187) Google Scholar). This hypothesis is also supported by the fact that VEGF is known to promote proliferation and survival of endothelial cells and that most of its effects appear to be mediated through VEGFR-2 (9Ferrara N. J. Mol. Med. 1999; 77: 527-543Crossref PubMed Scopus (1067) Google Scholar). VEGF and its receptors have also been shown to play an important role in adult hematopoiesis. VEGFR-2 has been found to be expressed on a subset of hematopoietic stem cells that can differentiate into hematopoietic or vascular endothelial cells, depending on the culture conditions (10Ziegler B.L. Valtieri M. Porada G.A. De Maria R. Muller R. Masella B. Gabbianelli M. Casella I. Pelosi E. Bock T. Zanjani E.D. Peschle C. Science. 1999; 285: 1553-1558Crossref PubMed Scopus (408) Google Scholar, 11Peichev M. Naiyer A.J. Pereira D. Zhu Z. Lane W.J. Williams M. Oz M.C. Hicklin D.J. Witte L. Moore M.A. Rafii S. Blood. 2000; 95: 952-958Crossref PubMed Google Scholar, 12Gehling U.M. Ergun S. Schumacher U. Wagener C. Pantel K. Otte M. Schuch G. Schafhausen P. Mende T. Kilic N. Kluge K. Schafer B. Hossfeld D.K. Fiedler W. Blood. 2000; 95: 3106-3112Crossref PubMed Google Scholar). Recent studies have shown that VEGF can recruit both hematopoietic cells (mainly through VEGFR-1) and endothelial progenitors (through VEGFR-2) to distant sites in vivo. This recruitment of marrow precursors may be critical in tumor angiogenesis (13Hattori K. Dias S. Heissig B. Hackett N.R. Lyden D. Tateno M. Hicklin D.J. Zhu Z. Witte L. Crystal R.G. Moore M.A. Rafii S. J. Exp. Med. 2001; 193: 1005-1014Crossref PubMed Scopus (593) Google Scholar). Furthermore, inhibition of VEGF and/or its receptors has recently been shown to reduce the number of hematopoietic progenitors in vivo (14Gerber H.P. Malik A.K. Solar G.P. Sherman D. Liang X.H. Meng G. Hong K. Marsters J.C. Ferrara N. Nature. 2002; 417: 954-958Crossref PubMed Scopus (583) Google Scholar). However, because of the numerous members of the VEGF ligand and receptor family, it is difficult to study the specific effects of VEGFR-2 signaling without the interference of other VEGF receptors such as VEGFR-1, VEGFR-3 (Flt-4), and the neuropilins (15Larrivee B. Karsan A. Int. J. Mol. Med. 2000; 5: 447-456PubMed Google Scholar). Recently, the unique signaling effects of some hematopoietic receptors (Flt-3, Mpl, granulocyte-colony stimulating factor receptor, c-Kit) have been studied by fusing the signaling domain of these receptors to an FK506-binding protein (FKBP) that can be specifically activated using synthetic FKBP ligands (16Blau C.A. Peterson K.R. Drachman J.G. Spencer D.M. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 3076-3081Crossref PubMed Scopus (99) Google Scholar, 17Jin L. Siritanaratkul N. Emery D.W. Richard R.E. Kaushansky K. Papayannopoulou T. Blau C.A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8093-8097Crossref PubMed Scopus (61) Google Scholar, 18Jin L. Asano H. Blau C.A. Blood. 1998; 91: 890-897Crossref PubMed Google Scholar, 19Blau C.A. Prog. Exp. Tumor Res. 1999; 36: 162-171Crossref PubMed Google Scholar, 20Jin L. Zeng H. Chien S. Otto K.G. Richard R.E. Emery D.W. Blau C.A. Nat. Genet. 2000; 26: 64-66Crossref PubMed Scopus (96) Google Scholar, 21Richard R.E. Wood B. Zeng H. Jin L. Papayannopoulou T. Blau C.A. Blood. 2000; 95: 430-436Crossref PubMed Google Scholar, 22Otto K.G. Jin L. Spencer D.M. Blau C.A. Blood. 2001; 97: 3662-3664Crossref PubMed Scopus (14) Google Scholar). This system has permitted the demonstration that the self-renewal and differentiation of hematopoietic progenitors can be influenced through distinct, receptor-initiated signaling pathways (23Zeng H. Masuko M. Jin L. Neff T. Otto K.G. Blau C.A. Blood. 2001; 98: 328-334Crossref PubMed Scopus (38) Google Scholar). In this study, we used this inducible dimerization strategy to specifically study the effects of VEGFR-2 signaling on hematopoietic progenitors. It has been shown that neuropilin-1 is a receptor for VEGF and acts as a co-receptor that enhances the function of VEGF through VEGFR-2 (24Zachary I. Gliki G. Cardiovasc. Res. 2001; 49: 568-581Crossref PubMed Scopus (564) Google Scholar). Furthermore, VEGFR-2 has been shown to heterodimerize with VEGFR-1 (25Kendall R.L. Wang G. Thomas K.A. Biochem. Biophys. Res. Commun. 1996; 226: 324-328Crossref PubMed Scopus (613) Google Scholar). The strategy we used allows us to study the unique signaling properties of VEGFR-2, without any interference from other VEGF receptors, allowing us to exclude the effects of neuropilin, or heterodimerization with VEGFR-1. To specifically study the unique signaling effects of VEGFR-2, we fused the cytoplasmic domain of this receptor, which contains the split tyrosine kinase domain, to a mutated FKBP12 domain that harbors a phenylalanine to valine mutation at amino acid 36. Although other studies have shown the signaling effects of VEGFR-2 by using VEGFR-2-specific ligands, such as VEGF-E (26Meyer M. Clauss M. Lepple-Wienhues A. Waltenberger J. Augustin H.G. Ziche M. Lanz C. Buttner M. Rziha H.J. Dehio C. EMBO J. 1999; 18: 363-374Crossref PubMed Scopus (408) Google Scholar), the use of a nontoxic chemical inducer of dimerization, AP20187 (Ariad Pharmaceuticals), allows us to study with high specificity VEGFR-2 signaling pathways in a cell autonomous manner. This strategy also allows us to rule out any potential signaling effects that could be triggered by neuropilin-1, which acts as a co-receptor for VEGF, enhancing its binding to VEGFR-2 (15Larrivee B. Karsan A. Int. J. Mol. Med. 2000; 5: 447-456PubMed Google Scholar). Moreover, AP20187 is well tolerated in vivo, which allows its use in studying specific signaling pathways in vivo and evaluation of its potential use in therapeutic strategies. Our studies show that VEGFR-2 activation results in maintenance of the hematopoietic progenitor population in conditions of cytokine starvation. This effect is mainly due to increased survival of hematopoietic progenitors through the PI 3-kinase/Akt pathway, although the Erk1/2 MAP kinase pathway may also be involved. Our results suggest that VEGFR-2 may be important in maintaining hematopoiesis by promoting the survival of hematopoietic progenitors, through the activation of PI 3-kinase, and possibly through Erk1/2 MAP kinases. Retroviral Vectors and Packaging Cell Lines—The intracellular domain of VEGFR-2, which exhibits tyrosine kinase activity, was fused to a modified FKBP12 domain that can dimerize in response to an analog of FK1012, AP20187 (27Whitney M.L. Otto K.G. Blau C.A. Reinecke H. Murry C.E. J. Biol. Chem. 2001; 276: 41191-41196Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar) (Ariad Pharmaceuticals, Inc., Cambridge, MA). The construct we used in this study contained a myristoylation sequence, two modified FKBP12 domains, the signaling domain of VEGFR-2, and a C-terminal hemagglutinin (HA) epitope tag (Fig. 1A). A chimeric fusion protein containing an amino-terminal myristoylation signal, two copies of a mutated FKBP12, followed by a carboxyl-terminal HA epitope tag, was released from the PC4M-Fv2E vector (Ariad) using EcoRI and BamHI and inserted into the pEGFP-C1 plasmid (Clontech, Mississauga, Canada). An SpeI-linked fragment encoding the intracellular domain of human VEGFR-2 was PCR-amplified from the full-length cDNA (gift of C. Patterson) using the following primer pairs: 5′-GACTAGTAAGCGGGCCAATGGAGGG-3′ and 5′-GACTAGTAACAGGAGGAGAGCTCAGTG-3′. The amplicon was digested with SpeI, gel-purified, and subcloned into SpeI-digested pBluescript. After sequence confirmation, the fragment was released from pBluescript by SpeI digestion, gel-purified, and subcloned into the SpeI site of the pEGFPC1-FKBP12 plasmid. The FKBP-VEGFR-2 fragment was released using HindIII-XbaI digestion, overhanging ends filled in with Klenow fragment of DNA polymerase I, and cloned into the HpaI site of a previously described murine stem cell virus-internal ribosome entry site-enhanced green fluorescent protein (MIG) vector based on an original vector kindly provided by R. Hawley (28Antonchuk J. Sauvageau G. Humphries R.K. Exp. Hematol. 2001; 29: 1125-1134Abstract Full Text Full Text PDF PubMed Scopus (183) Google Scholar). Ecotropic packaged virus was generated using the following procedure. Phoenix-AMPHO cells (R. Nolan) were transfected with the vector plasmids using Fugene (Roche Applied Science, Laval, Canada) according to the instructions of the manufacturer. Medium was changed after 24 h, and transfected cells were cultured for another 24 h in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). Supernatant was then harvested, filtered, and used for repeated infections of GP+E86 ecotropic packaging cells in the presence of 8 μg/ml polybrene (Sigma). After sorting for GFP expression, transduced GP+E86 cells were plated at limiting dilution. Individual clones were tested, and the highest titer clone was selected by titration of supernatants on NIH 3T3 cells. Cell Lines—HMEC-1 endothelial cells (Center for Disease Control and Prevention, Atlanta, GA) were cultured in MCDB medium (Invitrogen) supplemented with 10% FBS and 10 μg/ml epidermal growth factor (EGF) (Sigma). HMEC-1 cells were retrovirally transduced using amphotropic packaged virus obtained by harvesting the supernatant of Phoenix-AMPHO cells transfected with vector plasmids 48 h prior to supernatant collection. Hematopoietic progenitors were extracted from the femurs and tibias of C3Pep mice (cross between C3H/HeJ and Pep3b) treated 4 days previously with 150 mg/kg 5-fluorouracil (Amersham Biosciences) and cultured for 48 h in Iscove's modified Dulbecco's medium (IMDM) supplemented with a serum substitute (BIT (Stem Cell Technologies Ltd., Vancouver, Canada)), 10–4m 2-mercaptoethanol, 40 μg/ml low density lipoproteins (Sigma), 1 ng/ml Flt3-ligand, 300 ng/ml stem cell factor (SCF), and 20 ng/ml interleukin-11 (Stem Cell Technologies). After stimulation, cells were harvested and infected by either cocultivation with irradiated (1500 centigrays, x-ray) GP+E86 viral producer cells or by the addition of virus-containing supernatant from the GP+E86 producer cells in fibronectin-coated dishes. Both infection protocols involved 48-h growth on tissue culture plates with the above cytokine combination and with the addition of 5 μg/ml protamine sulfate (Sigma). Following infection, bone marrow cells were plated in the same medium for another 2 days. Cells were then sorted for GFP expression (FACS 440; Becton Dickinson). Viability Assays—Sorted bone marrow cells were plated in IMDM supplemented with 10% FBS with or without the addition of 100 nm AP20187. We found that this dose-induced maximal survival effect on hematopoietic progenitors (data not shown). Cells were harvested at various times and counted on a hemacytometer. CFC Assay—Transduced GFP-positive bone marrow cells were grown in IMDM supplemented with 10% FBS, with or without 100 nm AP20187, for 7 and 14 days. At these time points, hematopoietic clonogenic progenitor frequencies were determined by plating 20,000 bone marrow cells in methylcellulose medium containing 50 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6, and 3 units/ml erythropoietin (Methocult GF M3434; Stem Cell Technologies). Resultant colonies were scored after 10 days of incubation. CFU-Spleen (CFU-S12) Assay—Transduced GFP-positive bone marrow cells were cultured in IMDM supplemented with 10% FBS with or without 100 nm AP20187 for 7 days. 25,000 cells were injected in the tail vein of lethally irradiated (900 centigrays, using a 137Cs source) B6C3 mice (cross between C3H/HeJ and C57Bl/6J). 12 days later, mice were sacrificed, spleens were harvested and fixed in Telleyesniczky's solution, and hematopoietic colonies were counted. Immunofluorescence—For BrdUrd staining, sorted GFP-positive bone marrow cells were cultured in IMDM supplemented with 10% FBS for 2 days and then treated for 2 h with 10 μm BrdUrd with or without 100 nm AP20187. Cytospin preparations of bone marrow cells were fixed with 4% paraformaldehyde for 5 min, washed with phosphate-buffered saline, and permeabilized with ice-cold methanol for 1 min. Slides were then incubated for 20 min at 37 °C with 2 n HCl to denature DNA. Slides were blocked in phosphate-buffered saline, 5% goat serum, 0.1% Triton X-100 for 10 min, followed by a 1-h incubation with primary antibody (anti-BrdUrd conjugated with AlexaFluor 594 (Molecular Probes, Inc., Eugene, OR), 1:50 dilution in phosphate-buffered saline, 5% goat serum, 0.1% Triton X-100). After washing, nuclear DNA was stained with 4′,6-diamidino-2-phenylindole (1 μg/ml), and slides were mounted in anti-fading solution. For activated caspase 3 staining, cytospin preparations of hematopoietic progenitors grown in culture for 14 days in IMDM containing 10% FBS were stained using the same protocol as above (the DNA denaturation step was omitted), and the following antibodies were used: anti-activated caspase 3 (BD Pharmingen, San Diego, CA) and goat anti-rabbit Ig conjugated with Texas Red (Molecular Probes). Immunoblotting—Proteins from total cellular extracts were separated by SDS-PAGE and assessed by immunoblotting as previously described (29Duriez P.J. Wong F. Dorovini-Zis K. Shahidi R. Karsan A. J. Biol. Chem. 2000; 275: 18099-18107Abstract Full Text Full Text PDF PubMed Scopus (86) Google Scholar). Antibodies against phosphorylated VEGFR-2 and total and phosphorylated Akt and Erk MAP kinase were obtained from Cell Signaling Technology (Mississauga, Canada). Anti-HA antibody was obtained from Babco (Richmond, CA). The kinase inhibitors LY294002 and U0126 were obtained from Calbiochem. Statistical Analysis—A two-tailed Student t test was used to determine differences between treated and untreated cultures. p values < 0.05 were considered statistically significant. Activation of VEGFR-2 Delays Loss of Murine Hematopoietic Progenitors—To study the effect of VEGFR-2 signaling in primary bone marrow cells independently of other VEGF receptors, including VEGFR-1, VEGFR-3, neuropilin-1, or neuropilin-2 (15Larrivee B. Karsan A. Int. J. Mol. Med. 2000; 5: 447-456PubMed Google Scholar), or the presence of endogenous VEGF, we used a strategy to dimerize the intracellular domain of VEGFR-2 with a chemical inducer, AP20187. This strategy has previously been used to study the functional role of hematopoietic receptors such as Mpl, Flt-3, and c-Kit (21Richard R.E. Wood B. Zeng H. Jin L. Papayannopoulou T. Blau C.A. Blood. 2000; 95: 430-436Crossref PubMed Google Scholar, 22Otto K.G. Jin L. Spencer D.M. Blau C.A. Blood. 2001; 97: 3662-3664Crossref PubMed Scopus (14) Google Scholar). We cloned the intracellular domain of VEGFR-2 and fused it to a modified FKBP domain that can be specifically dimerized with a chemical inducer, AP20187 (Fig. 1A). When transduced into HMEC-1 cells or murine bone marrow cells, this construct gave a 110-kDa protein (Fig. 1B), which mainly localized to the cytoplasmic membrane when unstimulated (Fig. 1C). Stimulation of HMEC-1 cells with 10 nm AP20187 for 0–30 min, resulted in progressive translocation of the fused VEGFR-2 construct from the cytoplasmic membrane to the cytoplasm. Phosphorylation of the construct was observed as soon as 30 s after stimulation with 10 nm AP20187 in HMEC cells and remained over a period of at least 30 min (Fig. 1D). To investigate the effect of VEGFR-2 in hematopoietic cells, bone marrow from mice treated with 5-fluorouracil to activate bone marrow precursor cells was harvested and transduced with the VEGFR-2 fusion construct. As a control, the empty MIG vector was used. After sorting, transduced GFP-positive cells were plated in IMDM supplemented with 10% FBS with or without 100 nm AP20187, and cell number was counted at days 5, 7, and 14. We found that cell number decreased rapidly, indicating the necessity of cytokines for the survival of bone marrow cells. However, in marrow cells in which the VEGFR-2 construct was dimerized by the addition of AP20187, we observed a smaller decrease in cell number (Fig. 2A). After two weeks in culture, cell numbers in bone marrow control cultures were 2.5-fold lower than the ones in which VEGFR-2 was dimerized. This effect was not observed in VEGFR-2-transduced cells that did not receive AP20187, indicating that dimerization of VEGFR-2 is required for maintaining hematopoietic cell numbers. We next tested whether dimerization of VEGFR-2 has an additive effect on medium supplemented with hematopoietic cytokines that provide optimal growth conditions (30Thorsteinsdottir U. Sauvageau G. Humphries R.K. Blood. 1999; 94: 2605-2612Crossref PubMed Google Scholar). Transduced bone marrow cells were cultured in medium containing cytokines that are known to induce hematopoietic cell proliferation (IL-3, IL-6, and SCF), with or without 100 nm AP20187 (Fig. 2B). With these growth conditions, we did not observe any significant change when VEGFR-2 was dimerized in comparison with the control cells, suggesting that VEGFR-2 does not signal a proliferative effect that is synergistic with these hematopoietic cytokines. To test whether VEGFR-2 can preserve the viability and activity of hematopoietic progenitors in the absence of hematopoietic cytokines, VEGFR-2 and control cells were cultured in cytokine-free medium for 7 and 14 days with or without the addition of dimerizer, after which cells were plated in methylcellulose medium to assay for hematopoietic progenitors. We found that dimerization of VEGFR-2 maintained hematopoietic progenitor potential in liquid culture. Over a 2-week period in culture, we observed an 8-fold decrease in the number of progenitors in control bone marrow cultures. In contrast, when the FKBP-VEGFR-2 construct was dimerized with AP20187, we observed a 3-fold increase in the maintenance of progenitors over control cultures, consistent with the findings in Fig. 2 (Fig. 3A). Although VEGFR-2 dimerization maintained the hematopoietic progenitor population for a period of 2 weeks in the absence of other cytokines, we did not observe a significant change in the proportion of different hematopoietic progenitors as measured by the CFC assay (Fig. 3B). This result suggests that VEGFR-2 promotes hematopoietic cell survival and/or proliferation but does not affect differentiation of hematopoietic progenitors. To confirm that VEGFR-2 can independently maintain the multipotent hematopoietic progenitor population, we utilized the CFU-S12 assay following liquid culture of bone marrow cells for 7 days in cytokine-free medium. Colonies were enumerated in each of the spleens harvested 12 days following injection of bone marrow cells (Fig. 4A). As seen in Fig. 4B, VEGFR-2 dimerization resulted in a 5-fold increase in the proportion of CFU-S12 cells, compared with bone control marrow cultures. These results suggest that VEGFR-2 can maintain the activity and viability of primitive hematopoietic progenitors in the absence of other exogenous cytokines. VEGFR-2 Does Not Increase S-phase Entry in Hematopoietic Precursors—It is known that, in endothelial cells, VEGF can induce cell proliferation. It has been suggested that this effect is mainly mediated through VEGFR-2 (9Ferrara N. J. Mol. Med. 1999; 77: 527-543Crossref PubMed Scopus (1067) Google Scholar). We tested whether dimerization of VEGFR-2 also resulted in bone marrow cell proliferation, which could account in part for the delay in the loss of hematopoietic progenitors that we observed. Bone marrow cells were grown in cytokine-free medium for 2 days, then treated with BrdUrd with or without AP20187 for 2 h. Cytospins of cells were then labeled with an anti-BrdUrd antibody (Fig. 5A). We found that dimerization of VEGFR-2 did not result in a greater proportion of cells which incorporated BrdUrd, indicating that VEGFR-2 signaling alone may not be sufficient to induce proliferation of hematopoietic progenitors (Fig. 5B). VEGFR-2 Activation Reduces the Number of Apoptotic Cells in Hematopoietic Precursors—It has also been shown that VEGF can induce antiapoptotic signaling through phosphatidylinositol 3′-kinase (PI 3-kinase) in endothelial cells subjected to serum deprivation (31Gerber H.P. McMurtrey A. Kowalski J. Yan M. Keyt B.A. Dixit V. Ferrara N. J. Biol. Chem. 1998; 273: 30336-30343Abstract Full Text Full Text PDF PubMed Scopus (1722) Google Scholar). Since we observed a delay in loss of progenitors when VEGFR-2 is dimerized, we postulated that this effect was caused by an inhibition of apoptosis, since VEGFR-2 dimerization alone did not affect proliferation of hematopoietic progenitors. It has been shown that caspase 3 is present in hematopoietic precursor cells and is activated during apoptosis (32Nicholson D.W. Thornberry N.A. Trends Biochem. Sci. 1997; 22: 299-306Abstract Full Text PDF PubMed Scopus (2172) Google Scholar, 33Zermati Y. Garrido C. Amsellem S. Fishelson S. Bouscary D. Valensi F. Varet B. Solary E. Hermine O. J. Exp. Med. 2001; 193: 247-254Crossref PubMed Scopus (351) Google Scholar). To test whether VEGFR-2 inhibits hematopoietic cell apoptosis, transduced bone marrow cells were subjected to cytokine deprivation and incubated with or without AP20187 for 14 days. At this point, cytospins were made and stained for the activated form of caspase 3 (Fig. 6A). We found that the proportion of apoptotic cells was 2-fold lower in bone marrow cells in which VEGFR-2 was dimerized compared with bone marrow control cultures (Fig. 6B). Hence, inhibition of apoptosis through VEGFR-2 signaling would explain in part the maintenance of hematopoietic progenitors observed. VEGFR-2 Activates the PI 3-Kinase and Erk MAP Kinase Pathways—Since VEGFR-2 dimerization reduces the amount of apoptotic cells, we examined signaling pathways known to be induced by VEGF in endothelial cells. In particular, the PI 3-kinase/Akt and the MAP kinase pathways are both implicated in VEGF signaling and have potential roles in cell survival (31Gerber H.P. McMurtrey A. Kowalski J. Yan M. Keyt B.A. Dixit V. Ferrara N. J. Biol. Chem. 1998; 273: 30336-30343Abstract Full Text Full Text PDF PubMed Scopus (1722) Google Scholar, 34Thakker G.D. Hajjar D.P. Muller W.A. Rosengart T.K. J. Biol. Chem. 1999; 274: 10002-10007Abstract Full Text Full Text PDF PubMed Scopus (218) Google Scholar). To determine the kinetics of activation of Akt and Erk1/2 by VEGFR-2, endothelial cells transduced with MIG or MIG-FKBP/VEGFR-2 were starved overnight in medium supplemented with 5% FBS and then treated with AP20187 for 0–60 min. Membranes were reprobed with total Akt or Erk as a loading control. Following dimerization of VEGFR-2, we found that both Akt and Erk1/2 were activated. Akt phosphorylation peaked between 10 and 20 min (Fig. 7A), whereas maximum Erk1/2 phosphorylation was observed between 20 and 30 min (Fig. 7B). Activation of Akt was biphasic, with a second peak of phosphorylation after 60 min (Fig. 7A). This biphasic activation of Akt in response to VEGFR-2 dimerization was observed in three independent experiments. We next checked wheth" @default.
• W2004456466 created "2016-06-24" @default.
• W2004456466 creator A5002974357 @default.
• W2004456466 creator A5014878691 @default.
• W2004456466 creator A5024703985 @default.
• W2004456466 creator A5038736461 @default.
• W2004456466 creator A5083812935 @default.
• W2004456466 creator A5085605849 @default.
• W2004456466 date "2003-06-01" @default.
• W2004456466 modified "2023-10-10" @default.
• W2004456466 title "Vascular Endothelial Growth Factor Receptor-2 Induces Survival of Hematopoietic Progenitor Cells" @default.
• W2004456466 cites W1502896205 @default.
• W2004456466 cites W1563402441 @default.
• W2004456466 cites W1589194933 @default.
• W2004456466 cites W1963876488 @default.
• W2004456466 cites W1970910346 @default.
• W2004456466 cites W1973929883 @default.
• W2004456466 cites W1978408457 @default.
• W2004456466 cites W1980969801 @default.
• W2004456466 cites W2002049222 @default.
• W2004456466 cites W2004907588 @default.
• W2004456466 cites W2006383190 @default.
• W2004456466 cites W2008018400 @default.
• W2004456466 cites W2022234182 @default.
• W2004456466 cites W2026038921 @default.
• W2004456466 cites W2030025004 @default.
• W2004456466 cites W2031835897 @default.
• W2004456466 cites W2044664461 @default.
• W2004456466 cites W2045247659 @default.
• W2004456466 cites W2046516822 @default.
• W2004456466 cites W2049110705 @default.
• W2004456466 cites W2063810599 @default.
• W2004456466 cites W2067807708 @default.
• W2004456466 cites W2070081704 @default.
• W2004456466 cites W2070732456 @default.
• W2004456466 cites W2071497118 @default.
• W2004456466 cites W2076088666 @default.
• W2004456466 cites W2082890245 @default.
• W2004456466 cites W2087921363 @default.
• W2004456466 cites W2093498435 @default.
• W2004456466 cites W2096773218 @default.
• W2004456466 cites W2112343158 @default.
• W2004456466 cites W2118644071 @default.
• W2004456466 cites W2127432537 @default.
• W2004456466 cites W2137533053 @default.
• W2004456466 cites W2149185747 @default.
• W2004456466 cites W2155454547 @default.
• W2004456466 cites W2158316748 @default.
• W2004456466 cites W2161235995 @default.
• W2004456466 cites W2167732166 @default.
• W2004456466 cites W2168736535 @default.
• W2004456466 cites W2169221044 @default.
• W2004456466 cites W2169248308 @default.
• W2004456466 cites W2173808243 @default.
• W2004456466 cites W2314008482 @default.
• W2004456466 cites W2330980944 @default.
• W2004456466 cites W2406608326 @default.
• W2004456466 cites W4247904703 @default.
• W2004456466 cites W4249388929 @default.
• W2004456466 cites W43337559 @default.
• W2004456466 doi "https://doi.org/10.1074/jbc.m212158200" @default.
• W2004456466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12668684" @default.
• W2004456466 hasPublicationYear "2003" @default.
• W2004456466 type Work @default.
• W2004456466 sameAs 2004456466 @default.
• W2004456466 citedByCount "39" @default.
• W2004456466 countsByYear W20044564662012 @default.
• W2004456466 countsByYear W20044564662013 @default.
• W2004456466 countsByYear W20044564662015 @default.
• W2004456466 countsByYear W20044564662016 @default.
• W2004456466 countsByYear W20044564662017 @default.
• W2004456466 countsByYear W20044564662018 @default.
• W2004456466 countsByYear W20044564662023 @default.
• W2004456466 crossrefType "journal-article" @default.
• W2004456466 hasAuthorship W2004456466A5002974357 @default.
• W2004456466 hasAuthorship W2004456466A5014878691 @default.
• W2004456466 hasAuthorship W2004456466A5024703985 @default.
• W2004456466 hasAuthorship W2004456466A5038736461 @default.
• W2004456466 hasAuthorship W2004456466A5083812935 @default.
• W2004456466 hasAuthorship W2004456466A5085605849 @default.
• W2004456466 hasBestOaLocation W20044564661 @default.
• W2004456466 hasConcept C103041312 @default.
• W2004456466 hasConcept C109159458 @default.
• W2004456466 hasConcept C146285616 @default.
• W2004456466 hasConcept C14858245 @default.
• W2004456466 hasConcept C15215337 @default.
• W2004456466 hasConcept C15729860 @default.
• W2004456466 hasConcept C167734588 @default.
• W2004456466 hasConcept C201750760 @default.
• W2004456466 hasConcept C2777025900 @default.
• W2004456466 hasConcept C28328180 @default.
• W2004456466 hasConcept C502942594 @default.
• W2004456466 hasConcept C86803240 @default.
• W2004456466 hasConcept C95444343 @default.
• W2004456466 hasConceptScore W2004456466C103041312 @default.
• W2004456466 hasConceptScore W2004456466C109159458 @default.
• W2004456466 hasConceptScore W2004456466C146285616 @default.
• W2004456466 hasConceptScore W2004456466C14858245 @default.

• next